Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

A Fox Chase Cancer Center team is combining a rare longitudinal family cohort, whole-genome sequencing, AI-guided analysis, and laboratory validation to investigate why people with similar inherited susceptibility can experience very different cancer outcomes.

October 16, 2026

Vol.52 No.38

By Fox Chase Cancer Center

Clinical Roundup

BOT+BAL yield three-year survival in 48% of patients with recurrent ovarian cancer, phase Ib study finds

Botensilimab, a Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab, Agenus’ anti-PD-1 antibody, yielded a three-year overall survival rate of 48% (n=35), according to three-year follow-up results from the phase Ib C-800-01 study.

October 09, 2026

Vol.52 No.37

Cancer Policy

Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits

After a decade of litigation, Johnson and Johsnon has agreed to a settlement deal to resolve the some 69,000 lawsuits alleging the company’s talc-based baby powder caused ovarian cancer and mesothelioma.

August 07, 2026

Vol.52 No.31

By Claire Marie Porter

Clinical Roundup

Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds

Scientists at The Wistar Institute have identified a mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. The researchers showed that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy.

July 24, 2026

Vol.52 No.29

Clinical Roundup

Ovarian cancer cells use stress hormone signaling to shut down immune system, UTSW study finds

When activated in ovarian cancer cells, the receptor for the body’s primary stress hormone alters the tumor environment in ways that blunt immune response, according to research led by UT Southwestern Medical Center.

May 29, 2026

Vol.52 No.21

Drugs & Targets

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

FDA granted Fast Track designation to Debiopharm for the use of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123) for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer.

April 24, 2026

Vol.52 No.16

Ovarian Cancer Research Alliance launches a global AI-powered ecosystem to accelerate gynecologic cancer research

YOU MAY BE INTERESTED IN

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

BOT+BAL yield three-year survival in 48% of patients with recurrent ovarian cancer, phase Ib study finds

Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits

Chemo resistance in ovarian cancer may be reversible with existing drugs, Wistar study finds

Ovarian cancer cells use stress hormone signaling to shut down immune system, UTSW study finds

FDA grants Fast Track designation for lunresertib + zedoresertib for genomic-defined platinum-resistant ovarian cancer

Renew today!

Subscriber content

Never miss an issue!

Login